🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Lycia Therapeutics, Inc. (LYCA)
NASDAQ: LYCA · Real-Time Price · USD
33.07
+1.30 (4.09%)
At close: Nov 20, 2026, 4:00 PM EST
33.30
+0.23 (0.70%)
After-hours: Nov 20, 2026, 7:30 PM EST

Lycia Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
4.446.7414.94
Revenue Growth
--54.87%-
Gross Profit
12.936.7414.94
Selling, General & Admin
6.236.116.4
Research & Development
40.5140.5141.07
Operating Expenses
46.7446.6247.47
Operating Income
-33.81-39.88-32.53
Interest Expense
-0.03-0.03-0.04
Interest & Investment Income
3.734.836.19
Other Non Operating Income (Expenses)
-0.05-0.1-0.12
EBT Excluding Unusual Items
-30.16-35.18-26.5
Merger & Restructuring Charges
-0.12-1.53-
Pretax Income
-30.28-36.71-26.5
Income Tax Expense
-0.25-0.250.01
Net Income
-30.03-36.46-26.5
Net Income to Common
-30.03-36.46-26.5
Net Income Growth
---
Shares Outstanding (Basic)
141413
Shares Outstanding (Diluted)
141413
Shares Change
-5.22%-
EPS (Basic)
-2.09-2.59-1.98
EPS (Diluted)
-2.09-2.59-1.98
EPS Growth
---

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-33.79-51.56-30.77
Free Cash Flow Per Share
-2.35-3.66-2.30
Gross Margin
291.48%100.00%100.00%
Operating Margin
-762.32%-591.57%-217.82%
Profit Margin
-677.16%-540.87%-177.44%
Free Cash Flow Margin
-761.83%-764.81%-206.03%
EBITDA
-32.84-38.69-31.36
EBITDA Margin
---209.94%
D&A For EBITDA
0.971.191.18
EBIT
-33.81-39.88-32.53
EBIT Margin
---217.82%
SEC Filings: 10-K · 10-Q